Dr Pinakin V Parekh’s Post

The SELECT trial reveal that there are many mechanisms of semaglutide that could attribute for cardiovascular and obesity benefit (cardiovascular benefit, liver disease and inflammatory) independent of weight loss, ➡️hence this make it unwise to stop this medication once achieving target weight loss. ➡️Lack of heterogeneity in achieving primary composite endpoints within different subgroups ➡️achieving clinical significance and numerical reduction in all cause mortality. ➡️economical value is challenging ➡️previous supportive evidence for weight loss independent CVS protective actions of the GLP-1 agonist as in HARMONY Outcomes trial for Albiglutide in type 2 DM there was no body weight difference at 28 weeks, yet 22% reduction in MACE, driven by fewer MI events https://lnkd.in/e98ZtQGF

The incidence of metabolic dysfunction-associated steatohepatitis (MASH) is increasing globally along with increases in obesity, type 2 diabetes, and metabolic syndrome. Join us to gain insight into the management of patients at risk for MASH https://lnkd.in/eWsqcT2y

The ADA Releases 2024 Standards of Care in Diabetes. The key points from the update are: Emphasis on inclusive language that empowers individuals with diabetes. Updated recommendations for diagnostic testing and classification of diabetes. New guidelines for the use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems and expanded recommendations for individualized obesity treatment and weight management strategies. https://lnkd.in/g3TzxbuT

Understanding the role of glucose-dependent insulinotropic polypeptide in managing diabetes and obesity https://lnkd.in/eb3HQXNY https://lnkd.in/eiPY3PUs

Vault Bioventures spotlights the vital link between obesity and diabetes on this 22nd day of National Diabetes Awareness Month. Obesity is a key factor in over half of new diabetes cases each year. Recognizing and treating obesity as a chronic disease is essential in diabetes prevention and management. Key Insights - - A majority of those with type 2 diabetes are overweight or obese. - Effective obesity management can delay or prevent the onset of type 2 diabetes and is beneficial in treating it. - Modest weight loss can significantly improve glycemic control in type 2 diabetes. ADA’s Role - - The ADA's Standards of Care in Diabetes—2023 highlights the importance of obesity management in diabetes care. - ADA-funded research is exploring new treatment targets and interventions for effective weight management. Addressing obesity is a crucial step towards reducing diabetes risk. For more information, click the link. #DiabetesPrevention #ObesityAndDiabetes #HealthAwareness #nationaldiabetesawarenessmonth

4th SOPHIA General assembly meeting: Is Type 1 Diabetes a barrier to obesity treatment? 📢Although type 1 diabetes is traditionally considered a disease of lean people, overweight and obesity are becoming increasingly more common in individuals with type 1 diabetes. Ozempic, Trulicity, Jardiance, Mounjaro ... are all approved for glucose control in type 2 diabetes. Some of them also have additional indications reflecting their demonstrated benefits for cardiovascular disease, kidney health, and obesity. None of them are approved for people with type 1 diabetes. #JDRF #IHI #Type1Diabetes

https://lnkd.in/d_ymtGt9 Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT #ADA2024 American Diabetes Association @SEEDO - Sociedad Española para el Estudio de la Obesidad Vithas Novo Nordisk

Excess body weight is a significant risk factor for both diabetes and cardiovascular disease (CVD). The accumulation of adipose tissue can lead to insulin resistance, contributing to the development of type 2 diabetes. Additionally, obesity is associated with dyslipidemia, hypertension, and inflammation, all of which increase the likelihood of CVD. Maintaining a healthy weight is crucial in reducing the risk of these chronic conditions. Join us in this session with Dr. Shariq Masoodi and Dr. Supratik Bhattacharyya on May 3 at 9:00 p.m. to learn more. Click on the link to join: https://lnkd.in/gzsQRaQ6 #diabetes #cardiovasculardisease #hypertension #diabetesmanagement #obesity 

With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gyxJyBtK

https://lnkd.in/eH8pD6p3 This article was in The Times yesterday. I find it astounding that 1-million people are walking around with undiagnosed type 2 diabetes. This is not a condition to leave undiagnosed as you are setting yourself up for further health issues down the line such as cardiovascular disease. It is also a condition that develops through lifestyle choices such as inactivity, eating a high carb diet, drinking liquid sugar. It can be reversed with the right guidances and choices. In my clinic if I suspect blood sugar dysregulation, or heart issues I do run a cardiometabolic panel which gives really good biomarkers (blood) markers and then it is possible to implement a targeted approach to address. #cardiometabolic #bloodsugarcontrol #type2diabetes #neuropathy #functionalmedicine #naturopathy